Eudragit E as excipient for production of granules and tablets from Phyllanthus niruri L spray-dried extract
Related Experiment Video
Updated: Jul 13, 2026

Preparation Of Gushukang (GSK) Granules for In Vivo and In Vitro Experiments
Published on: May 9, 2019
Tatiane Pereira de Souza1, Ramón Martínez-Pacheco, José Luiz Gómez-Amoza
1Departamento de Farmácia, UFRN, Natal, Rio Grande do Norte, Brazil. tpsouza@ufrnet.br
Abstract:
The aim of this study was to investigate the feasibility of using Eudragit E as a granulating agent for a spray-dried extract from Phyllanthus niruri to obtain tablets containing a high dose of this product. The granules were developed by wet granulation and contained 2.5%, 5.0%, and 10.0% Eudragit E in the final product concentration. The tablets were produced on a single-punch tablet press by direct compression of granules using 0.5% magnesium stearate as a lubricant. The tablets were elaborated following a 2 x 3 factorial design, where Eudragit E concentration and compression force were the independent variables, and tensile strength and the extract release of the tablets were the dependent variables. All granules showed better technological properties than the spray-dried extract, including less moisture sorption. The characteristics of the granules were directly dependent on the proportion of Eudragit E in the formulation. In general, all tablets showed high mechanical resistance with less than 1% friability, less moisture sorption, and a slower extract release profile. The Eudragit E concentration and compression force of the tablets significantly influenced both dependent variables studied. In conclusion, Eudragit E was efficient as a granulating agent for the spray-dried extract, but additional studies are needed to further optimize the formulations in order to achieve less water sorption and improve the release of the extract from the tablets.
Related Concept Videos
Factors Influencing Drug Absorption: Pharmaceutical Parameters
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Pharmaceutical Equivalents
Oral Drug Delivery Systems: Delayed-Release Systems

